Quarterly report pursuant to Section 13 or 15(d)

Revenue - Narrative - Remaining Performance Obligation (Details)

v3.20.1
Revenue - Narrative - Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
$ in Millions
Mar. 31, 2020
USD ($)
Seattle Genetics  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation $ 23.8
AstraZeneca  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation 22.8
Les Laboratoires Servier and Institut de Recherches Internationales Servier  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation $ 10.9
License and Collaboration Agreement | AstraZeneca  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Performance obligation period 12 months